Curriculum Vitae

Brian T. Kalet
Department of Biochemistry & Molecular Biology
Colorado State University
Fort Collins, Colorado 80523
kalet@colostate.edu

EDUCATION

May 2008:
Ph.D. Biochemistry
December 2004:
M.S. Biochemistry
May 2002:
B.S. Biochemistry & Molecular Biology
  • Department of Biochemistry & Molecular Biology, University of Massachusetts at Amherst
  • Graduated Magna Cum Laude with Biochemistry and Molecular Biology Departmental Honors
  • 3.742 GPA
EXPERIENCE

2013 – Present:
Colorado State University, Department of Biochemistry & Molecular Biology


2010 – 2013:
Colorado State University, College of Veterinary Medicine & Biomedical Sciences

Postdoctoral Fellow:
2007 – 2008:
Sierra Sciences

Research Associate:
  • Participated in the discovery of telomerase inducers to slow the aging process
2005 – 2007:
University of Colorado, Department of Chemistry & Biochemistry

Research Associate:
2005:
Amgen, Biology – Amgen San Francisco

Graduate Intern:
  • Determined role of confidential protein expression on apoB secretion
2002 - 2005:
University of Colorado, Department of Chemistry & Biochemistry

Research Associate:
  • Elucidated mechanism of action of doxorubicin-formaldehyde conjugate doxazolidine
2001 - 2002:
AstraZeneca R&D, EST Biology, New Chemical Solutions

Undergraduate Intern:
  • Performed site-directed mutagenesis of Kv1.2 & cloned mutants into mammalian expression vector
  • Transfected CHO and RBL cell lines with aforementioned constructs and determined expression levels by immunohistochemistry
1999 - 2001:
AstraZeneca R&D, CNS Discovery, Gene Sciences

Undergraduate Intern:
  • Performed radioligand, fluo-ligand and biotinylated-ligand binding assays using viable cells and cell membranes
  • Established phagocytosis assay using carboxylated microspheres

1997 - 1999:
Marathon Biopharmaceuticals

Lab Maintainer:
  • Maintained Proteins, DNA, HPLC, Chemistry and Microbiology labs and Fermentation Suite
PUBLICATIONS
Cited 204 times.  (Source: Google Scholar, January, 2019)

Sholders AJ, Kalet BT.  (2016) Principles of Biochemistry.  Dubuque, Iowa: Great River Learning.

Kalet BT, Anglin SR, Handschy A, O'Donoghue L, Halsey C, Chubb L, Korch C, Duval DL.  Transcription factor Ets1 cooperates with estrogen receptor α  to stimulate estradiol-dependent growth in breast cancer cells and tumors.  PLoS One.  2013 July 9;8(7):e68815.

Koch TH, Barthel BL, Kalet BT, Rudnicki DL, Post GC, Burkhart DJ.  Anthracycline-formaldehyde conjugates and targeted prodrugs.  In Anthracyclines Chemistry and Biology II, Topics in Current Chemistry.  Krohn K, (Ed.), Vol. 283, Springer, Berlin 2008.

Kalet BT, McBryde MB, Espinosa JM, Koch TH.  Doxazolidine Induction of Apoptosis by a Topoisomerase II-independent Mechanism. J Med Chem.  2007 Sep 6; 50 (18): 4493-4500.

Burkhart DJ, Barthel BL, Post GC, Kalet BT, Nafie JW, Shoemaker RJ, Koch TH.  Design, Synthesis, and Preliminary Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases.  J Med Chem.  2006 Nov 30; 49 (24): 7002-12.

Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH.  Doxorubicin-formaldehyde  conjugates targeting αvβ3 integrin. Mol Cancer Ther.  Featured on the cover, 2004 Dec;3(12):1593-604.



PATENTS

Koch TH, Burkhart DJ, Post GC, Nafie J, Kalet BT, Barthel BL, Rudnicki, DL. Methods of Treating Cancer with Doxazolidine and Prodrugs Thereof.  Docket No. 2848-8PCT.  International Application No. PCT/US06/60367.  2006 Oct.

Koch TH, Coleman MP, Cogan PS, Burke PJ, Post GC, McKenzie A, Jackson K, Kalet BT, Burkhart DJ.  Design, Synthesis and the Use of Targeted Anti-Tumor and Antibiotic Drug-Formaldehyde Conjugates.  CU TTO File No. 2002.120B. 2004 Sep.
Comments